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1. Introduction 
Cardiovascular diseases – the main result of the generalized atherosclerosis are the 
leading cause of global mortality all over the world [1,2]. The number of atherosclerotic 
diseases - an ischemic stroke, coronary heart disease and peripheral artery disease 
increases every year [1]. Possibly, due to increase in the population age, better health care 
and improved survival the prevalence of heart diseases is still so high [3]. The 
cardiovascular mortality in the most developed countries also is very high [2,3]. About 
half of all deaths occures due to cardiovascular diseases, it‘s an over 4,35 million deaths 
each year in the 53 member states of the World Health Organization European Region and 
more than 1,9 million deaths each year in the European Union [2]. Moreover there is a 35 
billion euros damage due to working people production loss regarding to cardiovascular 
morbidity and mortality [2]. The cardiovascular mortality is still a problem not only in the 
European Union, but in the other developed countries as well. Atherosclerotic coronary 
artery disease was the most common cause of death in the United States in 2004. Men 
were more often affected, than women by a ratio of 4:1 and after age of 70 by ratio 1:1 [4]. 
In 2000 about 37 % of death in Canada were due to cardiovascular diseases [3]. They are 
still the main cause of mortality in Lithuania, as in the older Western European countries 
as well [5,6]. At the last decade, cardiovascular morbidity and mortality in Lithuania has 
not declined (Figure 1) [7,8]. 
In 2008 in Lithuania standartized cardiovascular mortality rate was 520,1 per 100 000 
population (Figure 2) [8]. Although in the last years cardiovascular mortality has a tendency 
to decrease, it‘s still very high [7]. Lithuanian mortality from coronary artery disease rate in 
2008 was 321,29 per 100 000 population (Figure 3) [7,8]. By the statistic data from the 
Lithuanian Institute of Hygiene, in 2011 56,3% of the people have died from cardiovascular 
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disease in Lithuania. In 2011, 20944 men and 20093 women have died, 47,7% and 62,7% due 
to coronary artery disease respectively [9]. 
The main cardiovascular disease - coronary heart disease - highly associated with an 
increased cardiovascular mortality, hospitalisation and patients disability, significantly 
raising the cost of medical care [6]. In 2009 it was 4283,39 per 100 000 population hospital 
discharge for cardiovascular diseases and 1311,8 for coronary artery disease in Lithuania 
(Figure 4,5) [8].  
In 2000 in Canada 7,3 billion dollars (17%) of total direct health care costs and 12,3 billion 
(14,5%) dollars of total indirect health care costs for all disease categories were attributed to 
cardiovascular diseases [3]. In the European Union, the economic cost of cardiovascular 
diseases in direct and indirect healthcare goes to 192 billion euros annually [1]. A total 
annual cost for person is vary from 50 euros in Malta to 600 euros in Germany, and 372 
euros in average [2].  
 
 
SDR – standartized death rate 
Figure 1. Age standartized cardiovascular mortality rate for Baltic States and all European Region 
dynamic. 
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SDR – standartized death rate 
Figure 2. Age standartized cardiovascular mortality rate per 100 000 population, 2008. 
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SDR – standartized death rate 
 
 
 
 
Figure 3. Age standartized mortality rate for coronary artery disease per 100 000 population, 2008. 
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Figure 4. Hospital discharges for the patients with cardiovascular diseases in 2009, per 100 000 
population. 
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Figure 5. Hospital discharges for the patients with coronary artery disease in 2009, per 100 000 
population. 
Epidemiological studies have evaluated a number of important risk factors for coronary 
artery disease, such as positive family history, particulary in the age less than 40 for men, 
and 50 for women, age, male gender, blood lipids abnormalities, diabetes, hypertension, 
loss of physical activity, smoking and others, not so substantial (high sensitivity C-
reactive protein, hyperfibrinogenemia etc.) [4,6,10-12]. Reducing one or more of these risk 
factors reduces the risk of major cardiac event accordingly [4]. There are a lot of evidence 
that lipoprotein disorder is the main pathogenesis of atherosclerosis. This relationship 
that was estimated century ago by Anitschkow is still important today [3,13]. Variuos 
epidemiological studies demonstrated a strong association between dyslipoproteinemia and 
coronary heart disease. There is a strong relation between serum cholesterol concentration  
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level and the coronary heart disease risk [14]. The Multiple Risk Factor Intervention Trial 
(MRFIT) in USA with 356222 men with different cardiovascular risk factors and 6-year 
follow-up period have shown that elevated total cholesterol blood concentration 
significantly increases cardiovascular risk [14,15]. In 2008, the authors published the report 
about the continuous follow-up for 25 years. The main finding was that total cholesterol is 
continuous and strong independent predictor for cardiovascular mortality. Estimated 
increased cardiovascular mortality risk at every total cholesterol level from 160 mg/dl (about 
4,14 mmol/l) and higher [15]. Abnormal lipids metabolism or excessive intake of cholesterol 
especially with a genetic predisposition, initiates the atherosclerosis. A lot of clinical studies 
established total cholesterol and low density lipoprotein cholesterol are associated with a 
great risk of coronary heart disease. The reduce of total cholesterol by 10% decreasing the 
risk of ischemic heart disease by 25% within 5 years [16]. Low density lipoprotein 
cholesterol reduction not only decreases cardiovascular events, but reduce total mortality as 
well [3,17]. Furthermore, large randomized controlled clinical trials established the low 
density lipoprotein cholesterol lowering benefits [10]. It is proved, the reduce of low density 
lipoprotein cholesterol by 1 mmol/l, decreasing the risk of acute cardiac events by 20%, 
cardiovascular mortality by 22% [1,11,16-18]. Treatment of lipoproteins disorder also 
decrease the development of new lesion, regenerates endothelial function and signally 
reduce cardiovascular events in treated patients [4]. However, the data based on the 
National Health And Nutrition Examination Survey (NHANES) study from 2005-2008 have 
estimated that 71 million adults (33,5%) in the USA had elevated low density lipoprotein 
cholesterol level, but only 34 million (48,1%) were treated and 23 million (33,2%) had 
reached target low density lipoprotein value. Though, comparing this data to the data from 
NHANES study in 1999-2002, the number of people with elevated low density lipoprotein 
level treated with lipids-lowering medications increased from 28,4% to 48,1% between 1999-
2002 and 2005-2008 periods. The prevalence of controled low density lipoprotein increased 
from 14,6% to 33,2% [17]. Although, statins significantly reduce low density lipoprotein 
cholesterol and coronary heart disease risk, substantial residual cardiovascular risk remains, 
even with very aggressive low density lipoprotein cholesterol values reduction [11,19,20]. 
However, atherosclerosis pathogenesis is multiple. It depends not only on low density 
lipoprotein cholesterol level, but also on genetic, environmental factors, infections, lifestyle 
factors and other diseases or condition [10-12]. More than a hundred different risk factors 
for atherosclerosis are estimated today. Although it is known many risk factors for coronary 
heart disease, the most of them are modifiable. Such as smoking cessation, treatment of 
dyslipidaemia, lowering of blood pressure can prevent the progression of atherosclerosis 
and major cardiovascular events [4]. One of the most important mechanisms of  
the atherosclerosis pathogenesis is Endothelial dysfunction [21]. In the early stages of 
atherosclerosis endothelian-dependent vasorelaxation disturbes due to oxidative stress and 
reduced nitric oxide bioavailability. Monocytes and T-lymphocytes adhesion occures. These 
inflammatory cells penetrate the cell wall, as well as lipid accumulation in the walls of blood 
vessels takes place. The inflammation and lipids accumulation make a plaque unstable, so it 
may occlude the vessel. Endothelial dysfunction is observed not only in the initial stage, but 
also in all other stages of atherosclerosis as well [21-23]. However, the main risk factors still  
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are male gender and older age (more common in women in menopause), heredity, 
hypertension, diabetes, smoking, stress, obesity, lack of physical activity, elevated low 
density lipoprotein cholesterol and total cholesterol and decrease high density lipoprotein 
cholesterol levels [6,10-12]. Numerous epidemiological studies have found reduced high 
density lipoprotein cholesterol as an independent risk factor for cardiovascular disease [24]. 
The Framingham study evaluated 43-44% increasing coronary events in patients with high 
density lipoprotein cholesterol < 40 mg/dL (1,03 mmol/l) [25]. Patients whose high density 
lipoprotein cholesterol less than 0,9 mmol/l (35 mg/dL) have 8 times higher risk of 
cardiovascular disease, versus those, whose high density lipoprotein cholesterol more than 
1,68 mmol/l (65 mg/dL) [26]. Studies demonstrates that declined high density lipoprotein 
cholesterol levels are relatively common in general population. 16-18% of men and 3-6% of 
women have a high density lipoprotein cholesterol level less than 0,9 mmol/l (35 mg/dL) 
[20]. Moreover, the reduced high density lipoprotein cholesterol level is a component of the 
metabolic syndrome – the great predictor of high cardiovascular risk. Experimental studies 
have found high density lipoprotein cholesterol as a potential antiatherogenic by following 
characteristics. Estimated high density lipoprotein cholesterol facilitates reverse cholesterol 
transport and delivers cholesterol from the smooth muscles into hepatic cholesterol uptake. 
So, harmfull atherogenic cholesterol parts, such as low density lipoprotein cholesterol, are 
catabolized and neutralized [27-29]. High density lipoprotein cholesterol acts as an 
antioxidant, reducing vascular oxidative stress and has anti-inflammatory properties, 
reducing vascular inflammation due to atherosclerosis. There are evidence high density 
lipoprotein cholesterol has a vasoprotective effect, facilitates blood vessel relaxation, play an 
important role in the inhibition of white blood cells chemotaxis and adhesion. Also it is 
known about an anti-apoptotic effect of high density lipoprotein cholesterol on endothelial 
cells. High density lipoprotein cholesterol enhances the proliferation and migration of 
Endothelial cells and endothelial progenitor cells and thereby promotes the restoration of 
the endothelium’s integrity. Finally, it has an antiplatelet/profibrinolitic effect, in this way 
reducing platelet aggregation and inactivating coagulation cascade [20,27-29]. Despite the 
evidence that reduced high density lipoprotein cholesterol is associated with an increased 
cardiovascular morbidity and mortality, the major guidelines in cardiology still do not 
recommend to initiate the treatment of dyslipidemia on high density lipoprotein cholesterol. 
So, dyslipoproteinemia is a major risk factor for atherosclerosis and coronary artery disease. 
Its‘ proper recognition and management can significantly reduce cardiovascular and total 
mortality rates [12]. Follow the American Heart Association and the National Heart, Lung 
and Blood Institute and the Adult Treatment Panel III guidelines it is recommended to start 
treat from the low density lipoprotein cholesterol. Recent clinical studies provide supporting 
evidence for low density lipoprotein cholesterol target values of less than 2,5 mmol/l (< 100 
mg/dl) for the prevention of coronary artery disease for the high cardiovascular risk patients 
and less thant 1,8 mmol/l (< 70 mg/dl) for the very high cardiovascular risk patients [1]. 
Studies demonstrate the significant decrease of atherosclerosis with aggressive reduction of 
low density lipoprotein cholesterol level in patients with coronary artery disease [3]. Only 
achieved target low density lipoprotein cholesterol value it is recommended to take care of 
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high density lipoprotein cholesterol. Studies evaluated, that high density lipoprotein 
cholesterol level more than 60 mg/dl (about 1,5 mmol/l) significantly reduce cardiovascular 
risk and can be named as „inverse risk factor“ [21]. The target high density lipoprotein 
cholesterol is over 1,03 mmol/l (40 mg/dL) for men and more than 1,29 mmol/l (50 mg/dL) 
for women [20].  
2. Lipoproteins disorder as a risk factor for cardiovascular mortality 
Today there are more than one lipoproteins disorder classification. The Frederickson, Lees 
and Levy‘s one was based on the lipoprotein fraction after separation by electrophoresis. 
This classification recognized chylomicrons, very low density cholesterol and low density 
cholesterol. However, the main limitation of this classification, that it does not include high 
density lipoprotein cholesterol. That‘s why the World Health Organisation, the European 
Atherosclerosis Society and the National Cholesterol Education Program have classified 
lipoproteins disorder on the basis of the absolute plasma level of lipids (total cholesterol and 
trygliceride) and lipoprotein cholesterol level (low density lipoprotein cholesterol and high 
density lipoprotein cholesterol) [12,30]. This classification sustained on biochemical 
characteristics of lipoproteins and lipids. The plasma lipids do not circulate freely in plasma. 
They are bound to proteins and transported as macromolecular complexes called 
lipoproteins [24]. In these complexes lipids are surrounded by a stabilizing coat of 
phospholipid. There are five principal types of lipoprotein particles in the blood: very low 
density lipoproteins, intermediate density, low density, high density lipoproteins and 
chylomicrons. They are structurally different by electrophoretic mobility and density after 
separation in the ultracentrifuge and by the function [14,24]. The lipoprotein density 
depends on amount of fats contained within it [31].  
Chylomicrons are the largest lipoproteins and synthesized in the small intestine from 
dietary fat and cholesterol [14,24,31]. They contain triglyceride from the intestine and a 
small amount of cholesterol. The main task of chylomicrons to transport the digestion 
products of dietary fat to the liver and peripheral tissue, where they are needed as a source 
of energy. In the circulation triglycerides are removed from chylomicrons via the action of 
lipoprotein lipase. If present in large amounts, such as after a fatty meal, chylomicrons cause 
the plasma to appear milky. Very low density lipoproteins are synthesized in the liver 
continuously and consists of triglyceride and cholesterol. Like chylomicrons they function 
primarily to distribute triglycerides to target sites such as adipose tissue and skeletal muscle 
where they are used for storage and energy [31]. It is the main body source of energy in 
prolonged fasting [14]. Like chylomicrons, they are removed due to lipoprotein lipase 
action. With removal of triglycerides and protein, very low density lipoproteins are 
converted to low density lipoproteins. High plasma levels of very low density lipoprotein 
cholesterol are to be found in familial hypertriglyceridaemia, diabetes mellitus, in people 
with a depressed thyroid function and in people with a high alcohol intake [31]. 
Intermediate density lipoproteins – one of the source of low density lipoproteins 
production. Last-mentioned are the main particles of lipids. They can deposit lipids into the 
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arterial wall and initiate atherosclerosis. Low density lipoprotein cholesterol are cholesterol-
rich particles. About 70% of plasma cholesterol find in this form. Low density lipoprotein 
cholesterol have a main role in transporting the cholesterol manufactured in the liver to the 
tissues, where it is used. When low density lipoprotein cholesterol binds to low density 
lipoprotein cholesterol receptors on the cell surface, low density lipoprotein cholesterol is 
taken into the cell and broken down into free cholesterol and amino acids. Disorders involving 
a defect in or lack of low density lipoprotein cholesterol receptors are usually characterised by 
high plasma cholesterol levels. In the case of the inherited familial hypercholesterolemia the 
cholesterol excess cannot be cleared efficiently from the blood and therefore accumulates, 
caused coronary heart disease. And the last particles – high density lipoproteins are produced 
in liver and intestine. They are composed of 50% protein, with phospholipid and cholesterol as 
the remainder [31]. They transport lipids away from the periphery. The transfer of pro-
atherogenic particles, such as very low density lipoproteins to the liver for the reverse 
cholesterol transport is one of the most important role of high density lipoprotein cholesterol. 
In this process harmful pro-atherogenic particles are transporting from the periphery to the 
liver for the reverse cholesterol transport and neutralizing [14,21]. It is well known low density 
lipoprotein cholesterol is one of the major factor for the development of atheroma. 
Atherosclerotic plaque consist of accumulated intracellular and extracellular lipids, smooth 
muscle cells, connective tissue, and glycosaminglycans. 
There are two main hypotheses to explain the pathogenesis of atherosclerosis: the lipid 
hypothesis and the chronic endothelial injury hypothesis. Both of them are interrelated. The 
endothelial dysfunction is an initial stage of atherosclerosis, occures due to oxidative stress 
and sub-endothelial accumulation of lipids. Low density lipoprotein cholesterol undergo 
oxidation and become local cytotoxic. Macrophages migrate into the sub-endothelial space, 
take up lipids and become “foam” cells. The earliest detectable lesion of atherosclerosis is 
the fatty strip. This strip consists of foam cells full of lipids. As the process progress, the 
smooth muscle cells also migrate into the lesion. At this stage, the lesion may be 
hemodynamically insignificant. But endothelial dysfunction exists and it’s ability to limit the 
entry of lipoproteins into the vessel is impaired [4]. So, the elevation of plasma low density 
lipoprotein cholesterol level results in penetration of low density lipoprotein cholesterol into 
the vessel wall, lipids accumulation in macrophages and smooth muscle cells. Endothelial 
injury produces loss of endothelium, adhesion of platelets to subendothelium, aggregation 
of platelets, chemotaxis of monocytes and T-cell lymphocytes, and release of growth factors 
that induce migration of smooth muscle cells from media to intima, where synthesize 
connective tissue and proteoglycans and forms a fibrous plaque. Low density lipoprotein 
cholesterol is cytotoxic and may cause endothelial injury and stimulate smooth muscle 
growth. Touched endothelial cell are functionally impaired and increase the uptake of low 
density lipoprotein cholesterol from plasma [24]. Growing atherosclerotic plaque may cause 
a severe stenosis that can progress to total arterial occlusion. Eventually the plaque may 
become calcified. Some plaques, reached in lipids and inflammatory cells, as macrophages, 
covered with a thin fibrous cap may undergo spontaneous rupture, resulting in cascade of 
events, stimulates thrombosis and ends in acute ischaemic event [4,24]. 
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Hypercholesterolemia occures either from overproduction or defective clearance of very low 
density lipoprotein cholesterol or from increased conversion of very low density lipoprotein 
cholesterol to low density lipoprotein cholesterol. Overproduction of very low density 
lipoprotein cholesterol by liver may be caused by obesity, diabetes, alcohol consumption, 
nephrotic syndrome or genetic disorders. Each of this conditions can result in increased low 
density lipoprotein cholesterol and trygliceride levels. When dietary cholesterol reaches the 
liver, elevates intracellular cholesterol level. Due to this, low density lipoprotein cholesterol 
receptor synthesis is suppressed. This suppression occurs at the level of transcription of the 
low density lipoprotein cholesterol gene. A reduced number of receptors results in higher 
levels of plasma low density lipoprotein cholesterol and total cholesterol [24]. Today, it 
appears, that high density lipoprotein cholesterol assist in the mobilization of low density 
lipoprotein cholesterol [4]. Cardiovascular risk increases progressively with elevated of low 
density lipoprotein cholesterol and with a decrease in high density lipoprotein cholesterol 
level. Studies demonstrated that each decrease in high density lipoprotein cholesterol level 
by 1 mg/dl (0,0259 mmol/l) elevating cardiovascular risk by 2-3%. [20]. And contrarily, each 
increase in high density lipoprotein cholesterol level by 1 mg/dl (about 0,02 mol/l) lowering 
cardiovascular mortality by 6%, independently of low density lipoprotein cholesterol level 
[20,32]. Similarly, The Treating to New Target study evaluated high density lipoprotein 
cholesterol as a more significantly predictive for cardiovascular events comparing with low 
density lipoprotein cholesterol [21,33]. High density lipoprotein cholesterol is protective 
through multiple mechanisms. There are some new points in the high density lipoprotein 
cholesterol role and effects on atherosclerosis. Recently published studies showed the 
antooxidative role of high density lipoprotein cholesterol. Due to this effect the reduction of 
vascular oxidative stress is occured. It is thought, this can contribute to the atheroprotective 
effects. Supposedly, high density lipoprotein cholesterol decreases inflammatory process, 
stops the proliferation and migration of endothelial cells and has anti-apoptotic effects on 
them. All of this contributes to the anti-atherosclerotic effect [21]. High density lipoprotein 
cholesterol also affects the platelets function and haemostatic cascade [14]. 
The prevalence of hypercholesterolemia differ in the world. In 1996 in Taiwan 41,5% men 
and 19,6% of women had abnormal rates of plasma cholesterol [34]. In 1995 in Holand 19,2% 
of men and 12,4% of women have total cholesterol more than 6,5 mmol/l [35]. In 1999-2000 
in Europe the European Action on Secondary Prevention through Intervention to Reduce 
Events (EUROASPIRE) study have been performed. The prevalence of high total cholesterol 
have been declined in Europe 1995-2000 from 86,2 till 58,8% In 2000 58,8% of the population 
have total cholesterol more than 5,0 mmol/l [36]. In 2006-2007 The European Society of 
Cardiology carried out the EUROASPIRE III survey in 76 medical centers in 22 European 
countries (Belgium, Bulgaria, Cyprus, Croatia, The Czech Republic, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, the Netherlands, Romania, Russian 
Federation, Slovenia, Spain, Turkey and UK). The total 13935 participants with established 
coronary artery disease were reviewed and 8966 were interviewed 6 months after acute 
coronary event. 76,5% of all the patients had elevated total cholesterol and low density 
lipoprotein cholesterol. For 51% the total cholesterol more than 4,5 mmol/l was estimated and 
only for one half of them a total cholesterol goal (<4,5 mmol/l) was reached with lipid-lowering 
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medications, despite of the rather high rate of the statins prescription (80,7%). So, this study 
showed that one of the most important risk factor for cardiovascular mortality - 
dyslipoproteinemia control was inadequate and most of the patients did not achieve the 
targets defined in the guidelines [37]. By the data from MONICA project with 39 population 
from the 21 countries, in 2003 the main total cholesterol in Kaunas, Lithuania was near 6 
mmol/l for men and 6,5 mmol/l for women. Females from Lithuania were at the top of all 
countries, whereas the men were about an average. 15 countries evaluated higher levels of 
total cholesterol for men [38]. One of the meta-analysis showed that the highest protective 
effect can be get treating high risk patients with very high total cholesterol level [39]. 
Regarding to the existing evidence on lipoproteins disorder, treatment and also due to 
increased cardiovascular mortality in Lithuania we started the clinical data. At this study we 
have evaluated independent risk factors for one year cardiovascular mortality for the patients 
with acute and chronic coronary syndromes. Lipoprotein disorder was one of the most 
important risk factor for one year cardiovascular mortality. 
3. Methods 
A total of 3268 patients with coronary heart disease who were selected for this study. The 
data was collected by a standardized questionnaire. A total of 1865 (728 women and 1137 
men) with acute and chronic coronary heart disease, male and female, aged from 20 years 
till more than 80 years were reexamined after one year. Risk factors for coronary heart 
disease were evaluated. Lipoprotein disorder was definable as low density lipoprotein 
cholesterol level in twelve-hour fasting venous blood samples more than 3 mmol/l, total 
cholesterol level – more than 5,2 mmol/l, high density lipoprotein cholesterol level less than 
1,2 mmol/l for women and less than 1,0 mmol/l for men. Due to medical history and data on 
admission patients were attributed to chronic or acute coronary syndrome. The myocardial 
infarction and unstable angina were attributed to acute coronary syndromes. Stable angina – 
to chronic coronary syndrome. Myocardial infarction was diagnosed according to the World 
Health Organisation guidelines: angina pain and equivalent, ischemic signs on ECG (Q 
wave, ST and T changes) and an increase in troponin I more than 0,05 mg/l. Unstable angina 
diagnosis confirmed with the angine syndrome, ischemic changes on the ECG without 
increasing enzymes in the blood and with angiography assessment of the coronary artery. 
Stable angina determined using a standard clinic, ECG, exercise test and angiography. 
4. Statistical analysis 
The statistical analysis was performed using SPSS (Statistical Package for Social Science) 
version 13 and Microsoft Office Excel 2003 statistical programs. Descriptive statistics was 
used for the quantitative data analysis. Categorical data have been summarized as 
frequencies and percentages, and for comparisons, chi-square test have been used. 
Univariate and multivariate logistic regression analysis was used for the risk assessment. 
One year mortality risk was evaluated by isolated and standardized odds ratios with 95% 
confidence interval (CI). 
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5. Results 
The data from 1865 patients with chronic and acute coronary syndromes was analysed. For 
more than a half of the patients an acute coronary syndrome was diagnosed. The 
participants were mostly men (61%). 54,7% of the patients had a reduced level of high 
density lipoprotein cholesterol (less than 1,0 mmol/l for male, and less than 1,2 mmol/l for 
female), for about 32% an increased total cholesterol and low density lipoprotein cholesterol 
levels for each were evaluated. About 20,5% of the patients with decreased high density 
lipoprotein cholesterol level have elevated low density lipoprotein cholesterol level together. 
Nearly 90% of women with diagnosed dyslipidemia had a reduced high density lipoprotein 
cholesterol, whereas total cholesterol and low density lipoprotein cholesterol levels were 
elevated in about one-third of the females. The proportion in these atherogenic lipids in men 
was about 30% for everyone. 7,6% of the patients had died within one year. The one year 
cardiovascular mortality was similar for men and women, also for the patients with acute or 
chronic coronary syndrome. Nearly 22% of died patients had an increased levels of total 
cholesterol and low density lipoprotein cholesterol. For more than 67% of them the decrease 
of high density lipoprotein cholesterol was evaluated. The majority of the patients (50,5%) 
with acute coronary syndrome and more than 80% with stable angina had a reduced high 
density lipoprotein cholesterol (Table 1).  
 
 
High LDL1
n(%) 
Low HDL2
n(%) 
High TC3, 
n(%) 
Total, n(%) 
one-year CV 
mortality, n(%) 
Total 588 (31,5) 1021 (54,7) 594 (31,8) 1865 (100) 
Medical 
history      
Acute 
coronary 
syndrome 
371(35,3) 531 (50,5) 359 (34,2) 1050(56,3) 90(8,6) 
Chronic 
coronary 
syndrome 
217(36,5) 490(82,5) 235(39,6) 815(43,6) 52(8,7) 
Gender 
Female 241(33,1) 654(89,8) 264(36,2) 728(39) 55(7,5) 
Male 347(30,5) 367(32,2) 330(29) 1137(61) 87(7,6) 
Age groups 
< 70 years 419(35) 585(48,8) 433(36,2) 1197(64,2) 70(49,3) 
70-80 years 144(25,6) 368(65,6) 136(24,2) 561(30,1) 56(39,4) 
> 80 years 25(24,7) 63(62,4) 24(23,8) 101(5,4) 15(10,6) 
One year CV 
mortality 
31(21,8) 96(67,6) 31(21,8) 142(7,6) 
 
LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol, CV – cardiovascular; 1>3,0 
mmol/l, 2< 1,0 for males; < 1,2 mmol/l for females, 3> 5,2 mmol/l 
Table 1. Patients baseline characteristics. 
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For the 34-40% of the patients elevated low density lipoprotein cholesterol and total 
cholesterol were diagnosed (Figure 6,7). Patients distribution due to age shows Figure 8.  
 
 
 
Figure 6. Part of the patients with different total cholesterol level. 
 
 
 
Figure 7. Part of the patients with different low density lipoprotein cholesterol level. 
68.10%
25.10%
4.50% 2.30%
≤ 5,2 mmol/l
5,2-7 mmol/l
7,1-9 mmol/l
> 9 mmol/l
68.50%
27.10%
2.30% 2.10%
≤ 3 mmol/l
3-5 mmol/l
5,1-6 mmol/l
> 6 mmol/l
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Figure 8. Patients distribution due to the age. 
About 35-36% of the patients younger than 70 years, high total cholesterol and low density 
lipoprotein cholesterol levels were evaluated, the high density lipoprotein cholesterol have 
been decreased in nearly 49%. For the seniors (more than 70 years), the elevated total 
cholesterol and low density lipoprotein cholesterol were not so common (24-25% of the 
patients), but the reduced high density lipoprotein cholesterol was present more frequently 
(62-65%) (Table 1). Our data evaluated 1,8 times greater independent one year 
cardiovascular mortality risk for the patients with decreased high density lipoprotein 
cholesterol level (1,800, 95%CI 1,251-2,591, p=0,002). However, the assessment of the 
increased general values of the total cholesterol (more than 5,2 mmol/l) and low density 
lipoprotein cholesterol (more than 3,0 mmol/l) reduced mortality risk (0,575, 95%CI 0,382-
0,868, p=0,008 and 0,585, 95%CI 0,388-0,882, p=0,01 respectively) (Table 2).  
 
Risk factor OR (95%CI) p value 
TC 0,575(0,382-0,868) 0,008 
LDL 0,585 (0,388-0,882) 0,01 
HDL 1,800 (1,251-2,591) 0,002 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 2. Independent cardiovascular one year mortality rate. 
Though, one year cardiovascular death risk elevates with the increase of these parameters 
(total cholesterol more than 9,0 mmol/l, low density lipoprotein cholesterol more than 6,0 
mmol/l), although not significant (1,742, 95%CI 0,718-4,224, p=0,22 for total cholesterol more 
than 9,0 mmol/l and 1,167, 95%CI 0,408-3,339, p=0,773 for low density lipoprotein cholesterol 
more than 6,0 mmol/l). It is believed, the absence of the statistical significans due to small 
sampe size (Table 3).  
1.60%
8%
21.70%
33.10%
30.20%
5.40%
20-40
41-50
51-60
61-70
71-80
> 80
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Risk factor OR (95%CI) p value 
TC 
5,2-7 mmol/l 0,465(0,286-0,759) 0,002 
7,1-9 mmol/l 0,670(0,266-1,689) 0,396 
> 9 mmol/l 1,742(0,718-4,224) 0,22 
LDL 
3-5 mmol/l 0,524(0,333-0,825) 0,005 
5,1-6 mmol/l 0,788(0,240-2,588) 0,694 
> 6 mmol/l 1,167(0,408-3,339) 0,773 
HDL 
< 1,0 for males; < 1,2 mmol/l for females 1,800(1,251-2,591) 0,002 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 3. Independent cardiovascular one year mortality rate depending on lipoproteins level. 
For the patients with acute coronary syndrome one year cardiovascular mortality rate 
insignificantly increases with the total cholesterol more than 9,0 mmol/l (2,578, 95%CI 0,931-
7,136, p=0,068) and low density lipoprotein cholesterol more than 5 mmol/l (1,030, 95%CI 
0,305-3,481, p=0,963 for the level of 5-6 mmol/l, and 2,023, 95%CI 0,668-6,130, p= 0,213 for the 
level more than 6,0 mmol/l). Simillary, high density lipoprotein cholesterol less than 1,0 
mmol/l for men and less than 1,2 mmol/l for women increases one year cardiovascular 
mortality 1,4 times insignificantly (1,444, 95%CI 0,932-2,239, p=0,1) (Table 4).  
 
Risk factor OR (95%CI) p value 
TC 
>5,2 mmol/l 0,765(0,476-1,230) 0,269 
5,2-7 mmol/l 0,633(0,364-1,102) 0,106 
7,1-9 mmol/l 0,768(0,269-2,195) 0,623 
> 9 mmol/l 2,578(0,931-7,136) 0,068 
LDL 
> 3 mmol/l 0,724(0,451-1,164) 0,183 
3-5 mmol/l 0,613(0,360-1,041) 0,07 
5,1-6 mmol/l 1,030(0,305-3,481) 0,963 
> 6 mmol/l 2,023(0,668-6,130) 0,213 
HDL 
< 1,0 for males; < 1,2 mmol/l for females 1,444(0,932-2,239) 0,1 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 4. Cardiovascular one year mortality rate for the patients with acute coronary syndrome 
depending on lipoproteins level. 
For the patients with chronic coronary artery disease, only reduced high density lipoprotein 
cholesterol increased mortality risk, and this was great and significant (3,378, 95%CI 1,623-
7,028, p= 0,001). It surprised the increase of the total cholesterol and low density lipoprotein 
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cholesterol reduced one year cardiovascular mortality (almost in all groups significantly, 
p<0,05) (Table 5).  
 
Risk factor OR (95%CI) p value 
TC 
>5,2 mmol/l 0,247(0,097-0,628) 0,003 
5,2-7 mmol/l 0,183(0,056-0,595) 0,005 
7,1-9 mmol/l 0,420(0,056-3,160) 0,005 
> 9 mmol/l 0,667(0,087-5,124) 0,697 
LDL 
> 3 mmol/l 0,276(0,108-0,705) 0,007 
3-5 mmol/l 0,320(0,125-0,818) 0,017 
5,1-6 mmol/l - - 
> 6 mmol/l - - 
HDL 
< 1,0 for males; < 1,2 mmol/l for females 3,378(1,623-7,028) 0,001 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 5. Cardiovascular one year mortality rate for the patients with chronic coronary syndrome 
depending on lipoproteins level. 
Both in men and women with reduced high density lipoprotein cholesterol elevated 
mortality risk was evaluated (2,044, 95%CI 0,622-6,716, p= 0,239 for women, and 2,303, 
95%CI 1,483-3,577, p< 0,001 for men respectively). For females high total cholesterol (more 
than 9,0 mmol/l) and low density lipoprotein cholesterol (more than 6,0 mmol/l) 
insignificantly increased one-year cardiovascular mortality risk. For men, relevant total 
cholesterol level was more than 7,0 mmol/l and low density lipoprotein cholesterol more 
than 5,0 mmol/l, insignificantly (Table 6,7). 
 
Risk factor OR (95%CI) p value 
TC 
>5,2 mmol/l 0,236(0,105-0,530) 0 
5,2-7 mmol/l 0,123(0,038-0,4) 0 
7,1-9 mmol/l 0,263(0,035-1,963) 0,193 
> 9 mmol/l 2,0(0,550-7,239) 0,292 
LDL 
> 3 mmol/l 0,372(0,179-0,773) 0,008 
3-5 mmol/l 0,283(0,119-0,674) 0,004 
5,1-6 mmol/l 0,533(0,07-4,082) 0,544 
> 6 mmol/l 1,743(0,375-8,106) 0,479 
HDL 
< 1,0 for males; < 1,2 mmol/l for females 2,044(0,622-6,716) 0,239 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 6. Cardiovascular one year mortality rate for females depending on lipoproteins level. 
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Risk factor OR (95%CI) p value 
TC 
>5,2 mmol/l 0,926(0,568-1,510) 0 
5,2-7 mmol/l 0,844(0,484-1,470) 0,548 
7,1-9 mmol/l 1,050(0,366-3,017) 0,928 
> 9 mmol/l 1,540(0,450-5,272) 0,491 
LDL 
> 3 mmol/l 0,755(0,458-1,246) 0,008 
3-5 mmol/l 0,722(0,421-1,239) 0,238 
5,1-6 mmol/l 1,014(0,233-1,239) 0,985 
> 6 mmol/l 0,892(0,207-3,852) 0,879 
HDL 
< 1,0 for males; < 1,2 mmol/l for females 2,303(1,483-3,577) 0 
TC – total cholesterol, LDL- low density lipoprotein cholesterol, HDL – high density lipoprotein cholesterol 
Table 7. Cardiovascular one year mortality rate for males depending on lipoproteins level. 
It was noticed, that a decrease in high density lipoprotein cholesterol – is an important and 
reliable cardiovascular mortality risk factor in middle-aged patients (40-60 years). For the 
41-50 years patients the mortality risk increases nearly 5 times when high density 
lipoprotein cholesterol level declines less than 1,0 mmol/l for men, and less than 1,2 mmol/l 
for women (4,985, 95%CI 1,230-20,196, p<0,05). In the 51-60 year group the risk of death 
increases 2,5 times with a similar levels of high density lipoprotein cholesterol significantly 
(2,572, 95%CI 1,094-6,106, p< 0,05) and with a total cholesterol more than 5,2 mmol/l 
insignificantly (1,073, 95%CI 0,462-2,495, p=0,87). A similar trend for the high density 
lipoprotein cholesterol was evaluated for the elderly patients, without significance (due to 
small sample size) (Table 8,9,10). 
 
Years OR (95%CI) p value
20-40 
41-50 0,591(0,147-2,383) 0,46 
51-60 0,610(0,238-1,564) 0,303 
61-70 0,581(0,258-1,312) 0,191 
71-80 0,771(0,395-1,504) 0,445 
>80 0,421(0,088-2,012) 0,279 
Table 8. Cardiovascular one year mortality rate depending on age groups for the patients with 
increased low density lipoprotein cholesterol level. 
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Years OR (95%CI) p value
20-40 1,545(0,087-27,358) 0,767 
41-50 4,985(1,230-20,196) 0,024 
51-60 2,572(1,094-6,106) 0,032 
61-70 1,155(0,568-2,347) 0,691 
71-80 1,227(0,675-2,232) 0,502 
>80 2,745(0,721-10,445) 0,139 
Table 9. Cardiovascular one year mortality rate depending on age groups for the patients with 
decreased high density lipoprotein cholesterol level. 
 
Years OR (95% CI) p value
20-40 2,111(0,118-37,722) 0,611 
41-50 0,265(0,054-1,293) 0,1 
51-60 1,073(0,462-2,495) 0,87 
61-70 0,485(0,207-1,137) 0,096 
71-80 0,654(0,321-1,334) 0,243 
>80 0,448(0,094-2,142) 0,314 
Table 10. Cardiovascular one year mortality rate depending on age groups for the patients with 
increased total cholesterol level. 
6. Discussion 
In the last decade, lack of evidence on low density lipoprotein cholesterol and high 
density lipoprotein cholesterol in the pathogenesis of coronary heart disease have 
appeared. Mostly long-term outcomes were evaluated by the previous studies on 
lipoprotein disorder. We decided to estimate impact of the dyslipoproteinemia to the one 
year survival. It is proved by another studies, that patients with very low high density 
lipoprotein cholesterol have much higher risk of severe cardiovascular event or 
cardiovascular death comparing with patients with normal high density lipoprotein 
cholesterol level. Lower high density lipoprotein cholesterol values are associated with a 
higher great cardiovascular events risk and a greater burden of atherosclerosis, even 
among the patients with reduced low density lipoprotein cholesterol level [33,40,41]. In 
another side, very low low density lipoprotein cholesterol level is a significant prognostic 
factor, improved survival for the patient with acute coronary syndrome and may be a 
target for the treatment. In this study first and foremost we found that reduced high 
density lipoprotein cholesterol are highly prevalent in a large cohort of the patients with 
coronary artery disease and tend to be associated with a significantly higher 
cardiovascular mortality risk. More than a half of the patients in our study had decreased 
high density lipoprotein cholesterol, and therefore the higher cardiovascular events and 
mortality risk, especially for the patients with stable angina. These data are similar to 
another studies [40]. Results from another studies showed that the prevalence of the 
elevated low density lipoprotein cholesterol increases with age [17]. By data from our 
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study it is not only the problem for the eldery patients. The prevalence of the impaired 
low density lipoprotein cholesterol by the gender was similar both for men and women 
and it was high for the patients with established coronary artery disease, taking notice 
that elevated low density lipoprotein cholesterol can be managed and controlled 
successfully with lifestyle changes, medications or a combination both of them. We have 
found that decreased high density lipoprotein cholesterol level is a significant 
independent risk factor for cardiovascular one year mortality. Interestingly, in another 
similar studies reduced high density lipoprotein cholesterol more often were found in 
young men. In our study 90% of females with coronary artery disease had a decreased 
high density lipoprotein cholesterol level. Also, insufficient high density lipoprotein 
cholesterol level more often have been found in eldery people. Although high density 
lipoprotein cholesterol less than 1,3 mmol/l for women has been widely considered as a 
cardiovascular risk factor, in the present study we selected a cutoff point of less than 1,2 
mmol/l as a lowest high density lipoprotein cholesterol value that allowed us to identify 
those females at risk of cardiovascular one year mortality. It have been evaluated that 
about 20% of participants of our study had reduced high density lipoprotein cholesterol 
with elevated low density lipoprotein cholesterol level together. So, it is let to suspect, 
that one year cardiovascular mortality risk for them have to be much higher. There are a 
lot of evidence, that decreased high density lipoprotein cholesterol significantly increases 
cardiovascular mortality risk in stable patients. Also, there are some studies, showed that 
reduced high density lipoprotein cholesterol is associated with a higher risk of adverse 
outcomes [40]. Some reports on lipoproteins did not evaluated cardiovascular mortality 
due to acute or chronic ischaemic syndrome. Comparing acute coronary syndrome and 
chronic coronary artery disease patients we have been evaluated the more important role 
of total cholesterol and low density lipoprotein cholesterol on cardiovascular one year 
mortality for acute patients, though not significant. In contrast, high density lipoprotein 
cholesterol was strong independent risk factor both for acute (not significant) and chronic 
patients. Suprisingly, total cholesterol more than 5,2 mmol/l and low density lipoprotein 
cholesterol more than 3,0 mmol/l reduced one year mortality risk both for acute and 
chronic patients significantly. Additionally, the previous studies showed the increased 
mortality rate due to elevated low density lipoprotein cholsterol, have not 
comprehensively evaluated the impact of different low density lipoprotein cholesterol 
and high density lipoprotein cholesterol lipoproteins levels on cardiovascular mortality. 
Lehto and al. evaluated, that among 35-64 years females with acute myocardial infarction 
total cholesterol more that 8 mmol/l significantly increases reccurence cardiovascular 
disease risk [42]. It was a reason to search an impact of different levels of low density 
lipoprotein cholesterol and total cholesterol on cardiovascular mortality risk for men and 
women. Our hypothesis was confirmed, as it became clear, that one year cardiovascular 
mortality risk sharply rises when signally increased total cholesterol more than 9 mmol/l 
and low density lipoprotein cholesterol more than 6 mmol/l, especially in women. The 
future major research need to evaluate a different lipoprotein and total cholesterol levels 
impact in cardiovascular mortality, not only in short term, but in long-term outcomes as 
well. It seems, the highest levels of lipids, that could be attributed to hereditary 
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dyslipoproteinemia, may be very important predicting cardiovascular mortality rates and 
reducing a cardiovascular death risk. As it was find earlier, high density lipoprotein 
cholesterol more predictive for middle-aged men. Similarly, our study evaluated the more 
important role of decreased high density lipoprotein cholesterol, especially for 51-60 years 
men with the chronic coronary artery disease for one year cardiovascular mortality.  
7. Conclusion 
Lipoproteins disorder is the main factor for development of the atherosclerosis and predicts 
cardiovascular mortality. The most important findings from our data concerns the inverse 
relationship between the high density lipoprotein cholesterol and cardiovascular mortality 
rates. This association is characterized by a high degree of generality and strength. 
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